BTIG Research Boosts Personalis (NASDAQ:PSNL) Price Target to $16.25

Personalis (NASDAQ:PSNL) had its price objective raised by equities research analysts at BTIG Research from $11.00 to $16.25 in a report issued on Monday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s target price would indicate a potential upside of 20.91% from the company’s current price.

PSNL has been the subject of a number of other reports. Lake Street Capital lowered shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target for the company. in a research note on Monday. Morgan Stanley boosted their target price on Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Needham & Company LLC downgraded Personalis from a “buy” rating to a “hold” rating in a research report on Monday. TD Cowen restated a “buy” rating on shares of Personalis in a research report on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $14.25.

Personalis Stock Up 0.7%

Shares of NASDAQ PSNL opened at $13.44 on Monday. Personalis has a fifty-two week low of $3.84 and a fifty-two week high of $16.39. The firm’s 50-day simple moving average is $11.24 and its 200 day simple moving average is $8.98. The stock has a market cap of $1.41 billion, a P/E ratio of -13.18 and a beta of 2.24.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The company had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. On average, sell-side analysts anticipate that Personalis will post -1.07 earnings per share for the current fiscal year.

Insider Transactions at Personalis

In other news, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the completion of the transaction, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,558,668.88. This trade represents a 29.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of Personalis stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $14.00, for a total transaction of $69,748.00. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at $2,783,662. This represents a 2.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 435,032 shares of company stock valued at $5,599,929 over the last three months. 4.20% of the stock is owned by corporate insiders.

Institutional Trading of Personalis

A number of large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its holdings in shares of Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after buying an additional 2,395 shares in the last quarter. Dynamic Technology Lab Private Ltd boosted its stake in shares of Personalis by 75.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after acquiring an additional 33,044 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Personalis by 55.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after acquiring an additional 101,706 shares in the last quarter. Focus Partners Wealth acquired a new position in shares of Personalis in the 1st quarter worth $47,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Personalis by 505.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock worth $193,000 after acquiring an additional 24,621 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors.

Key Stories Impacting Personalis

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: The Tempus deal gives Personalis shareholders a clear cash/stock exit value at $16.25 per share, creating a takeover premium versus recent trading levels. Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
• Positive Sentiment: The acquisition validates Personalis’ MRD and cancer-monitoring technology, which Tempus said will strengthen its AI-enabled precision oncology platform and expand its cancer recurrence-testing capabilities. Tempus to acquire Personalis for $1.5 billion
• Neutral Sentiment: Several investor-rights law firms, including Halper Sadeh, Brodsky & Smith, Ademi, and Julie & Holleman, have launched investigations into whether the sale terms are fair to shareholders, which may add headline noise but does not change the deal economics. Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?
• Neutral Sentiment: Analyst commentary has been mixed, with BTIG raising its price target to $16.25 while Needham downgraded the stock to hold, reflecting debate over valuation rather than a change in the merger terms. Analyst coverage references
• Negative Sentiment: Some market coverage notes that both PSNL and TEM traded lower after the deal announcement, suggesting investors may be concerned about execution risk, deal structure, or limited upside beyond the acquisition price. Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.